Steris Q1 adjusted profit beats estimates

) Overview Steris fiscal Q1 2026 revenue rises 9% to $1.4 bln Adjusted EPS for fiscal Q1 beats analyst expectations, per LSEG data Co raises fiscal 2026 revenue outlook, expecting 8-9% growth Outlook Steris expects fiscal 2026 revenue to increase 8-9% Still sees Adjusted EPS from continuing operations of $9.90 to $10.15 Company anticipates $820 mln free cash flow for fiscal 2026 Steris projects capital expenditures of $375 mln for fiscal 2026 Company sees tariffs reducing pre-tax profit by $45 mln Result Drivers FOREIGN CURRENCY - Revenue benefited from favorable foreign currency impacts, expected to continue throughout fiscal yr, per CEO Dan Carestio HEALTHCARE SEGMENT - Healthcare revenue grew 8%, driven by 13% service revenue growth and improved volume and price AST SEGMENT - Applied Sterilization Technologies revenue increased 13%, with significant growth in capital equipment revenue Key Details Metric Beat/Mis Actual Consensu s s Estimate Q1 Beat $2.34 $2.26 (8 Adjusted Analysts EPS ) Q1 Beat $231.20 $222.20 Adjusted mln mln (5 Net Analysts Income ) Q1 $1.40 Revenue bln continui ng operatio ns Analyst Coverage The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 7 “strong buy” or “buy”, 2 “hold” and no “sell” or “strong sell” The average consensus recommendation for the medical equipment, supplies & distribution peer group is “buy” Wall Street’s median 12-month price target for STERIS plc is $278.00, about 19.5% above its August 5 closing price of $223.87 The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 23 three months ago Press Release: (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)